Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.71 CAD
Change Today +0.01 / 1.43%
Volume 30.6K
As of 12:05 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONC) Snapshot

Open
C$0.70
Previous Close
C$0.70
Day High
C$0.72
Day Low
C$0.70
52 Week High
03/3/15 - C$1.74
52 Week Low
10/10/14 - C$0.45
Market Cap
83.8M
Average Volume 10 Days
107.3K
EPS TTM
C$-0.16
Shares Outstanding
118.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONC)

oncolytics biotech inc (ONC) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONC) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONC) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a cancer therapeutic that is in various clinical trials for human use. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Founded in 1998

oncolytics biotech inc (ONC) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$538.0K
Chief Financial Officer
Total Annual Compensation: C$284.2K
Chief Operating Officer and Director
Total Annual Compensation: C$370.5K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: $316.7K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $143.0K
Compensation as of Fiscal Year 2014.

oncolytics biotech inc (ONC) Key Developments

Oncolytics Biotech Inc. Announces Completion of Enrollment in Randomized Phase II Non-Small Cell Lung Cancer Study

Oncolytics Biotech Inc. announced that enrollment has been completed in a randomized Phase II study of REOLYSIN® in patients with previously treated advanced or metastatic non-small cell lung cancer ('NSCLC') (IND 211). The trial is being sponsored and conducted by the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario. The study is an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN® as a treatment for advanced or metastatic non-small cell lung cancer patients who have received previous chemotherapy. A total of 166 patients were enrolled. Patients with squamous cell histology were randomized to receive either REOLYSIN® given in combination with docetaxel (test arm) or docetaxel alone (control arm), while patients with non-squamous cell histology were randomized to receive either REOLYSIN® given in combination with pemetrexed (test arm) or pemetrexed alone (control arm). The primary objective of the trial is to evaluate the effect of REOLYSIN® in combination with standard salvage chemotherapy on the progression free survival of patients with advanced or metastatic non-small cell lung cancer. The secondary objectives are to determine the tolerability and toxicity of the therapeutic combination; to investigate additional potential measures of efficacy, including progression rates at three months, objective response rate and overall survival; and to explore potential molecular factors predictive of response. Although accrual is complete, patient follow-up will continue until planned analyses have been conducted.

Oncolytics Biotech Inc. Announce Resignation of Linda Hohol from the Board of Directors with Effect from August 5, 2015

Oncolytics Biotech Inc. announced that Linda Hohol resigned from the Board of Directors of the company effective August 5, 2015. Ms. Hohol has served as a Director since June 2014.

Oncolytics Biotech Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Oncolytics Biotech Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, loss before income taxes was $3,849,487 compared to $4,714,617 a year ago. Net loss was $3,850,258 compared to $4,718,163 a year ago. Net cash used in operating activities was $5,118,284 compared to $5,780,235 a year ago. Capital expenditures were $17,657 compared to $1,239 a year ago. Basic and diluted loss per common share was $0.03 compared to $0.05 a year ago. For the six months, loss before income taxes was $7,401,325 compared to $10,196,218 a year ago. Loss before income taxes was $58 million compared to loss before income taxes $306 million a year ago. Net loss was $7,402,096 compared to $10,203,614 a year ago. Net cash used in operating activities was $7,865,473 compared to $11,944,313 a year ago. Capital expenditures were $29,597 compared to $17,219 a year ago. Basic and diluted loss per common share was $0.07 compared to $0.12 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONC:CN C$0.71 CAD +0.01

ONC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONC.
View Industry Companies
 

Industry Analysis

ONC

Industry Average

Valuation ONC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.